This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights: Abbott Lab, Bio-Rad Lab and Hill-Rom Holdings
by Zacks Equity Research
Zacks Industry Outlook Highlights: Abbott Lab, Bio-Rad Lab and Hill-Rom Holdings
3 Stocks to Capitalize on the Buoyant Medical Products Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ABT, BIO and HRC are well-poised to gain from the prospects.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) on strong fiscal fourth-quarter results and progress in digital health.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Robust performance across the Roto-Rooter segment and sequential growth in VITAS admissions are driving the top line for Chemed (CHE).
Hill-Rom (HRC) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Strong underlying performance and continued recovery across all three business segments drove Hill-Rom's (HRC) fourth-quarter fiscal 2021 revenues.
Hill-Rom (HRC) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Hill-Rom (HRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect robust performance across all its business units.
Here's Why You Should Hold on to Hill-Rom (HRC) for Now
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) owing to strategic buyouts and continued expansion efforts in the digital health space.
Hill-Rom (HRC) New LT Strategy Aids, Y/Y Comparisons Ail
by Zacks Equity Research
Hill-Rom's (HRC) newly initiated long-term growth strategies through fiscal 2022, focusing on all four strategic priorities, look attractive at this moment.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise
by Zacks Equity Research
Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
by Debanjana Dey
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
Cardiovascular Systems (CSII) Treats 1st Patient With ViperCross
by Zacks Equity Research
Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.
Baxter's (BAX) Premix Norepinephrine Now Available in U.S.
by Zacks Equity Research
Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.
Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How
by Zacks Equity Research
Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.
Hill-Rom (HRC) Agrees to Get Acquired by Baxter, Shares Jump
by Zacks Equity Research
The transaction is expected to close by early 2022 subject to the approval of Hill-Rom (HRC) shareholders and the fulfillment of customary closing conditions.
Hill-Rom (HRC) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Hill-Rom (HRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Hill-Rom (HRC) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) on impressive third-quarter fiscal 2021 performance and raised 2021 guidance.
HRC vs. SRDX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. SRDX: Which Stock Is the Better Value Option?
Hill-Rom (HRC) PSS Growth Solid Despite Tough Y/Y Comparison
by Zacks Equity Research
Hill-Rom's (HRC) recent launches, including the Helion Integrated Surgical System in the United States, buoy optimism.
HRC vs. SRDX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. SRDX: Which Stock Is the Better Value Option?
Zimmer Biomet (ZBH) Recovery Rate Slows Down Amid Pandemic
by Zacks Equity Research
Zimmer Biomet (ZBH) sees slower recovery amid the emergence of a new strain of coronavirus in a number of markets, including Japan.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies in the second quarter and raised 2021 guidance.
Abiomed's (ABMD) Q1 Earnings and Revenues Beat, Margins Up
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.
BD (BDX) Beats on Q3 Earnings and Revenues, Ups '21 View
by Zacks Equity Research
Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal third quarter, thus driving up the overall top line.